MOLECULAR DOCKING STUDIES ON SCREENING AND ASSESSMENT OF SELECTED BIOFLAVONOIDS AS POTENTIAL INHIBITORS OF COVID-19 MAIN PROTEASE
DOI:
https://doi.org/10.22159/ajpcr.2020.v13i9.38485Keywords:
Binding energy, 6LU7, Antiviral, Rutin, Coronavirus, Medicinal plantsAbstract
Objectives: The objective of the study was to screen and assess the selected bioactive bioflavonoids in medicinal plants as potential coronaviruses (CoV) main protease (Mpro) inhibitors using molecular docking studies.
Methods: We have investigated several bioflavonoids which include apigenin, galangin, glycitein, luteolin, morin, naringin, resveratrol, and rutin. Nelfinavir and lopinavir were used as standard antiviral drugs for comparison. Mpro was docked with selected compounds using PyRx 0.8 and docking was analyzed by PyRx 0.8 and Biovia Discovery Studio 2019.
Results: The binding energies obtained from the docking of 6LU7 with native ligand, nelfinavir, lopinavir, apigenin, galangin, glycitein, luteolin, morin, naringin, resveratrol, and rutin were found to be −7.4, −8.3, −8.0, −7.8, −7.3, −7, −7.4, −7.6, −7.8, −6.9, and −9 kcal/mol, respectively.
Conclusion: From the binding energy calculations, we can conclude that nelfinavir and lopinavir may represent potential treatment options and apigenin, galangin, glycitein, luteolin, morin, naringin, resveratrol, and rutin found to possess the best inhibitors of CoV disease-19 main protease.
Downloads
References
Prajapa M, Sarma P, Shekhar N, Avti P, Sinha S, Kaur H, et al. Drug targets for corona virus: A systematic review. Indian J Pharmacol 2020;52:56-65.
Malik YS, Sircar S, Bhat S, Sharun K, Dhama K, Dadar M, et al. Emerging novel corona virus (2019-nCoV)-current scenario, evolutionary perspective based on genome analysis and recent developments. Vet Q 2020;40:68-78.
Morales AJ, MacGregor K, Kanagarajah S, Patel D, Schlagenhauf P. Going global-travel and the 2019 novel corona virus. Travel Med Infect Dis 2020;33:101578.
Zhang D, Wu K, Zhang X, Deng S, Peng B. In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel corona virus. J Integr Med 2020;18:152-8.
Lu H. Drug treatment options for the 2019-new corona virus (2019- nCoV). Biosci Trends 2020;14:69-71.
Yang H, Bartlam M, Rao Z. Drug design targeting the main protease, the Achilles’ heel of corona viruses. Curr Pharm Des 2006;12:4573-90.
Chang CK, Lo SC, Wang YS, Hou MH. Recent insights into the development of therapeutics against coronavirus diseases by targeting N protein. Drug Discov Today 2016;21:562-72.
Saif LJ. Animal coronaviruses: What can they teach us about the severe acute respiratory syndrome? Rev Sci Tech 2004;23:643-60.
Alsaadi JE, Jones IM. Membrane binding proteins of corona viruses. Future Virol 2019;14:275-86.
Xu Z, Peng C, Shi Y, Zhu Z, Mu K, Wang X. Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation. BioRxiv 2019;28:1-20.
Nijveldt RJ, Nood E, Hoorn D, Boelens PG, Norren KV, Leeuwen P. Flavonoids: A review of probable mechanisms of action apotential applications. Am J Clin Nutr 2001;74:418-25.
Kumar S, Pandey AK. Chemistry and biological activities of flavonoids: An overview. ScientificWorldJournal 2013;2013:1-6.
Ali E, Rahul, Naz F, Jyoti S, Siddique YS. Health functionality of apigenin: A review. Int J Food Propert 2017;20:1197-238.
Meyer JJ, Afolayan AJ, Taylor MB, Erasmus D. Antiviral activity of galangin isolated from the aerial parts of Helichrysum aureonitens. J Ethnopharmacol 1997;56:165-9.
Zhang L, Chen J, Chai W, Ni M, Sun X, Tian D. Glycitin regulates osteoblasts through TGF-β or AKT signaling pathways in bone marrow stem cells. Exp Ther Med 2016;12:3063-7.
Qian S, Qian P, Li X. Antiviral activity of luteolin against Japanese encephalitis. Virus 2016;15:112-6.
Gravina HD, Tafuri NF, Silva A, Fietto JL, Oliveira TT, Diaz MA et al. In vitro assessment of the antiviral potential of trans-cinnamic acid, quercetin and morin against equid herpesvirus 1. Res Vet Sci 2011;91:58-62.
Salehi B, Fokou PV, Sharifi-Rad M, Zucca P, Pezzani R, Martins N et al. The Therapeutic potential of naringenin: A review of clinical trials. Pharmaceuticals 2019;12:1-8.
Abba Y, Hasliza H, Hamzah H, Noordin MM. Antiviral activity of resveratrol against human and animal viruses. Adv Virol 2015;2015:1-7.
Ganeshpurkar A, Saluja AK. The pharmacological potential of rutin. Saudi Pharm J 2017;25:149-64.
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2012;64:4-17.
Giménez BG, Santos MS, Ferrarini M, Fernandes JP. Evaluation of block buster drugs under the rule-of-five. Pharmazie 2010;65:148-52.
Xavier GS, Michael S. Molecular docking studies on antiviral drugs for SARS. IJARCSSE 2015;5:75-9.
Xu J, Zhao S, Teng T, Abdalla AE, Zhu W. Systematic comparison of two animal-to-human transmitted human corona viruses: SARS-CoV-2 and SARS-CoV. Viruses 2020;12:244.
Liu RX, Zhang B, Jin Z, Yang H. The Crytal Structure of 2019-nCoV Main Protease in Complex with an Inhibitor N3; 2020. Available from: https://www.rcsb.org/structure/6lu7.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
